The EPO published patent application EP4167955A1 covering a PLGA nanoparticle drug delivery system loaded with CAPE and functionalized with Angiopep-2 peptide for targeted cancer therapy. The application claims priority to IPC classifications A61K 9/00, A61P 35/00, A61K 9/51, A61K 45/06, and A61K 35/644, with designated states covering all major European jurisdictions.

This is a patent publication notice with no compliance obligations or deadlines. Pharmaceutical companies, drug manufacturers, and healthcare entities involved in nanoparticle-based cancer therapeutics or targeted drug delivery should review the claims to assess potential freedom-to-operate considerations or licensing opportunities.